ESMO Young Oncologist Journal Club

The ESMO Young Oncologists Committee is proud to host the Young Oncologist Journal Club. On a regular basis (1-3 times a month), a committee member – or a specially invited young oncologists – provides you with an appraisal of an important clinical and/or translational article published in a major journal. The appraisers add their comments analysing the clinical relevance of the article and possible considerations.

Get involved by reading the review, share your thoughts and raise questions for discussion by logging in and commenting on the article. Commenting is reserved to ESMO Members only. We look forward to your input!

Submit an article

Filter

Topic Title Author
Lung and other thoracic tumours Pembrolizumab versus Chemotherapy (ct) for pd-l1 Positive Non-Small-Cell Lung Cancer (NSCLC) Julia Martinez Perez
Palliative and supportive care Measuring the Benefit of Palliative Care for Effective Integration into Standard Cancer Care Rita Canário
Breast cancer Metronomic Chemotherapy for Hormone Receptor–Negative Early Breast Cancer: A Negative Clinical Trial, With Promising Results Herman Perroud
Head and neck cancers Pembrolizumab in Head & Neck Cancer Mogens Bernsdorf
Palliative and supportive care The Anomaly of Anamorelin Bishal Gyawali
Endocrine cancers Everolimus for the Treatment of Advanced, Non-Functional Neuroendocrine Tumours of the Lung or Gastrointestinal Tract (RADIANT-4): a Randomised, Placebo-Controlled, Phase 3 Study Barbara Kiesewetter
Melanoma and other skin tumours Genetic Alterations in Cutaneous Melanoma – what do we know? Teresa Amaral, Ioanna Tampouri
Genitourinary cancers Cabozantinib in Advanced Renal-Cell Carcinoma Cátia Faustino
Genitourinary cancers PD-1 Blockade Sets a New Benchmark in Previously Treated Metastatic Renal Cell Carcinoma (mRCC) Mehmet Akif Öztürk
Breast cancer Have a Look Around: breast cancer relapse may be printed in the blood Leticia De Mattos-Arruda
Lung and other thoracic tumours Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial Yusuke Okuma
Lung and other thoracic tumours CheckMate of Nivolumab as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer Antonio Passaro and Raffaele Califano
Lung and other thoracic tumours Pembrolizumab Seems to be a New Immune Checkpoint Inhibitor Option for NSCLC, However is our Knowledge on Tumour Biomarkers Enough? Pedro Nazareth Aguiar Jr, Ramon Andrade de Mello
Lung and other thoracic tumours Ramucirumab as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer: have we got a new kid on the block? Antonio Passaro and Raffaele Califano
Lung and other thoracic tumours Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer Matthew Howell and Raffaele Califano